Structural/mechanistic insights into the efficacy of non-classical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates

5 years ago

Structural/mechanistic insights into the efficacy of non-classical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates

Christopher T. Lohans, Matthew B. Avison, James Spencer, Christopher J. Schofield, Kate J. Heesom, Philip Hinchliffe, Karina Calvopiña, Samar Johnson, Jürgen Brem, Ricky Cain, Colin W. G. Fishwick

Clavulanic acid and avibactam are clinically deployed serine β-lactamase inhibitors, important as a defence against antibacterial resistance. Bicyclic boronates are recently discovered inhibitors of serine and some metallo β-lactamases. Here we show that avibactam and a bicyclic boronate inhibit L2 (serine β-lactamase) but not L1 (metallo β-lactamase) from the extensively drug resistant human pathogen Stenotrophomonas maltophilia. X-ray crystallography revealed that both inhibitors bind L2 by covalent attachment to the nucleophilic serine. Both inhibitors reverse ceftazidime resistance in S. maltophilia because, unlike clavulanic acid, they do not induce L1 production. Ceftazidime/inhibitor resistant mutants hyper-produce L1, but retain aztreonam/inhibitor susceptibility because aztreonam is not an L1 substrate. Importantly, avibactam, but not the bicyclic boronate is deactivated by L1 at a low rate; the utility of avibactam might be compromised by mutations that increase this deactivation rate. These data rationalize the observed clinical efficacy of ceftazidime/avibactam plus aztreonam as combination therapy for S. maltophilia infections and confirm that aztreonam-like β-lactams plus non-classical β-lactamase inhibitors, particularly avibactam-like and bicyclic boronate compounds, have potential for treating infections caused by this most intractable of drug resistant pathogens. This article is protected by copyright. All rights reserved. Stenotrophomonas maltophilia is an important bacterial pathogen that causes severe infections. It can become resistant to all β-lactam antibacterials via mutations that enhance L1 and L2 β-lactamase production. Characterisation of the interactions between various β-lactamase inhibitors and L1 and L2, whole cell susceptibility tests and proteomic analysis of resistant mutants show that the monobactam aztreonam plus the non-β-lactam based β-lactamase inhibitors avibactam and a novel cyclic boronate are excellent combinations against S. maltophilia.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/mmi.13831